Regeneron Pharmaceuticals Inc RGO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Sanofi, Regeneron to Expand Alliance in Up to $8 Billion Deal — Update
-
Sanofi, Regeneron to Expand Alliance in Deal Valued at Up to $8 Billion
-
Regeneron Posts Higher 2Q Revenue, Sees Improving Profit
-
Regeneron Gets FDA, EMA Review of Cemdisiran in Generalized Myasthenia Gravis
-
U.S. plans to move physicians exposed to rare Ebola virus to Germany
-
Health officials declare Ebola outbreak a public health emergency
-
Regeneron, Sanofi Get Expanded Europe OK for Dupixent in Younger Children With CSU
-
Regeneron Gets FDA OK for Extended Eylea HD Dosing
Trading Information
- Previous Close Price
- €648.00
- Day Range
- €658.90–666.40
- 52-Week Range
- €464.70–732.90
- Bid/Ask
- €0.00 / €0.00
- Shares Outstanding
- 102.95M
- Market Cap
- $68.61B
- Volume/Avg
- 18 / 46
Key Statistics
- Price/Earnings (Normalized)
- 16.53
- Price/Sales
- 5.36
- Dividend Yield (Trailing)
- 0.48%
- Dividend Yield (Forward)
- 0.49%
- Dividend Payment Schedule
- Mar, Jun, Aug, Dec
- Total Yield
- 4.41%
Company Profile
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Value
- Total Number of Employees
- 15,410
- Website
- https://www.regeneron.com
Valuation
|
Metric
|
RGO
|
|---|---|
Price/Earnings (Normalized) | 16.53 |
Price/Book Value | 2.47 |
Price/Sales | 5.36 |
Price/Cash Flow | 17.85 |
Price/Earnings
RGO
Financial Strength
|
Metric
|
RGO
|
|---|---|
Quick Ratio | 2.63 |
Current Ratio | 3.34 |
Interest Coverage | 80.98 |
Quick Ratio
RGO
Profitability
|
Metric
|
RGO
|
|---|---|
Return on Assets (Normalized) | 12.70% |
Return on Equity (Normalized) | 16.48% |
Return on Invested Capital (Normalized) | 13.47% |
Return on Assets
RGO
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|#kslhC | LOCK|@wTT | $129B | |||
| Moderna Inc
MRNA
| LOCK|vxYGCC? | LOCK|XG | $90B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|M&RBR> | LOCK|<hsCP | $77B | |||
| argenx SE ADR
ARGX
| LOCK|QS#plv% | LOCK|HD% | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|gc<xDT | LOCK|b?y | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|?X@Q#@G | LOCK|#^PB | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|RFRwh%^v | LOCK|J$bb | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|G!@hR%X | LOCK|$rx | $24B | |||
| Incyte Corp
INCY
| LOCK|Mg%xFhg | LOCK|X? | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|wh?M<% | LOCK|t< | $14B |
United States